Implementation of the medicare part D prescription drug benefit is associated with antiretroviral therapy interruptions

AIDS and Behavior

Volumn 13, Issue 1, 2009, Pages 1-9

  Das Douglas, Moupali ^a,b,c,d   Riley, Elise D ^d   Ragland, Kathleen ^d   Guzman, David ^d   Clark, Richard ^d   Kushel, Margot B ^d   Bangsberg, David R ^a,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c AIDS Office San Francisco   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adherence; Cost related medication nonadherence; Cost sharing; HIV AIDS; Medicare; Treatment interruption

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; FEMALE; HEALTH BEHAVIOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KNOWLEDGE; MAJOR CLINICAL STUDY; MALE; MEDICARE; PATIENT COMPLIANCE; PRESCRIPTION;

ADULT; ANTI-HIV AGENTS; COHORT STUDIES; COST SHARING; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HIV INFECTIONS; HUMANS; MALE; MEDICARE PART D; MEDICATION ADHERENCE; MIDDLE AGED; SOCIOECONOMIC FACTORS; UNITED STATES;

EID: 58149098900     PISSN: 10907165     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10461-008-9401-5     Document Type: Article

References (52)

1. AS Adams SB Soumerai D Ross-Degnan 2001 The case for a Medicare drug coverage benefit: A critical review of the empirical evidence Annual Reviews of Public Health 22 49 61 10.1146/annurev.publhealth.22.1.49
2. A Ammassari A Antinori MS Aloisi MP Trotta R Murri L Bartoli 2004 Depressive symptoms, neurocognitive impairment, and adherence to highly active antiretroviral therapy among HIV-infected persons Psychosomatics 45 5 394 402 10.1176/appi.psy.45.5.394
3. A Ammassari MP Trotta R Murri F Castelli P Narciso P Noto 2002 Correlates and predictors of adherence to highly active antiretroviral therapy: Overview of published literature Journal of Acquired Immune Deficiency Syndromes 31 Supplement 3 S123 S127
4. J Ananworanich A Gayet-Ageron M Le Braz W Prasithsirikul P Chetchotisakd S Kiertiburanakul 2006 CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: Results of the staccato randomised trial Lancet 368 9534 459 465 10.1016/S0140-6736(06)69153-8
5. KZ Bambauer DG Safran D Ross-Degnan F Zhang AS Adams J Gurwitz 2007 Depression and cost-related medication nonadherence in Medicare beneficiaries Archives of General Psychiatry 64 5 602 608 10.1001/archpsyc.64.5.602
6. Bangsberg, D. R., Ware, N., & Simoni, J. M. (2006). Adherence without access to antiretroviral therapy in sub-Saharan Africa? AIDS, 20(1), 140-141; author reply 141-142.. doi: 10.1097/01.aids.0000196168.50303.31
7. SA Bozzette SH Berry N Duan MR Frankel AA Leibowitz D Lefkowitz 1998 The care of HIV-infected adults in the United States. HIV Cost and services utilization study consortium New England Journal of Medicine 339 26 1897 1904 10.1056/NEJM199812243392606
8. JA Cole H Norman LB Weatherby AM Walker 2006 Drug copayment and adherence in chronic heart failure: Effect on cost and outcomes Pharmacotherapy 26 8 1157 1164 10.1592/phco.26.8.1157
9. JA Cook MH Cohen J Burke D Grey K Anastos L Kirstein 2002 Effects of depressive symptoms and mental health quality of life on use of highly active antiretroviral therapy among HIV-seropositive women Journal of Acquired Immune Deficiency Syndromes 30 4 401 409
10. JA Cook D Grey J Burke-Miller MH Cohen K Anastos M Gandhi 2006 Effects of treated and untreated depressive symptoms on highly active antiretroviral therapy use in a US multi-site cohort of HIV-positive women AIDS Care 18 2 93 100 10.1080/09540120500159284
11. ER Cox C Jernigan SJ Coons JL Draugalis 2001 Medicare beneficiaries' management of capped prescription benefits Medical Care 39 3 296 301 10.1097/00005650-200103000-00009
12. C Danel R Moh A Minga A Anzian O Ba-Gomis C Kanga 2006 CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in West Africa (Trivacan ANRS 1269 trial): A randomised trial Lancet 367 9527 1981 1989 10.1016/S0140-6736(06)68887-9
13. WM El-Sadr JD Lundgren JD Neaton F Gordin D Abrams RC Arduino 2006 CD4+ count-guided interruption of antiretroviral treatment New England Journal of Medicine 355 22 2283 2296 10.1056/NEJMoa062360
14. JJ Ellis SR Erickson JG Stevenson SJ Bernstein RA Stiles AM Fendrick 2004 Suboptimal statin adherence and discontinuation in primary and secondary prevention populations Journal of General Internal Medicine 19 6 638 645 10.1111/j.1525-1497.2004.30516.x
15. Gibson, T. B., Mark, T. L., Axelsen, K., Baser, O., Rublee, D. A., & McGuigan, K. A. (2006a). Impact of statin copayments on adherence and medical care utilization and expenditures. American Journal of Managed Care, 12 Spec no., SP11-SP19.
16. TB Gibson TL Mark KA McGuigan K Axelsen S Wang 2006 The effects of prescription drug copayments on statin adherence American Journal of Managed Care 12 9 509 517
17. DP Goldman GF Joyce Y Zheng 2007 Prescription drug cost sharing: associations with medication and medical utilization and spending and health Journal of the American Medical Association 298 1 61 69 10.1001/jama.298.1.61
18. JP Hall NK Kurth JM Moore 2007 Transition to Medicare Part D: An early snapshot of barriers experienced by younger dual eligibles with disabilities American Journal of Managed Care 13 1 14 18
19. RD Hays CD Sherbourne RM Mazel 1993 The RAND 36-Item Health Survey 1.0 Health Economics 2 3 217 227 10.1002/hec.4730020305
20. AE Headen Jr NA Masia KJ Axelsen 2006 Effects of Medicaid access restrictions on statin utilisation for patients treated by physicians practising in poor and minority neighbourhoods Pharmacoeconomics 24 Suppl 3 41 53
21. HIV Medicine Association. (2007). HIV Medical Provider Medicare Part D Survey.
22. Hosmer, D. L. S. (1989). Applied Logistic Regression. New York: John Wiley and Sons.
23. J Hsu M Price J Huang R Brand V Fung R Hui 2006 Unintended consequences of caps on Medicare drug benefits New England Journal of Medicine 354 22 2349 2359 10.1056/NEJMsa054436
24. Kaiser Family Foundation. (2005). Medicare chart book (3rd ed.). Menlo Park: Henry J. Kaiser Family Foundation.
25. Kaiser Family Foundation. (2006a). The role of Part D for people with HIV/AIDS: coverage and cost of antiretrovirals under Medicare drug plans (No. #7548). Menlo Park: Henry J. Kaiser Family Foundation.
26. Kaiser Family Foundation. (2006b). The Medicare prescription drug benefit. Menlo Park, CA: Kaiser Family Foundation.
27. Kaiser Family Foundation. (2006c). Dual eligibles: Medicaid's role for low-income Medicare beneficiaries. Washington D.C.: Henry J. Kaiser Family Foundation.
28. X Li JB Margolick CS Conover S Badri SA Riddler MD Witt 2005 Interruption and discontinuation of highly active antiretroviral therapy in the multicenter AIDS cohort study Journal of Acquired Immune Deficiency Syndromes 38 3 320 328
29. JM Madden AJ Graves F Zhang AS Adams BA Briesacher D Ross-Degnan 2008 Cost-related medication nonadherence and spending on basic needs following implementation of Medicare Part D Journal of the American Medical Association 299 16 1922 1928 10.1001/jama.299.16.1922
30. JJ Mahoney 2005 Reducing patient drug acquisition costs can lower diabetes health claims American Journal of Managed Care 11 5 Suppl S170 S176
31. R Mojtabai M Olfson 2003 Medication costs, adherence, and health outcomes among Medicare beneficiaries Health Affairs (Millwood) 22 4 220 229 10.1377/hlthaff.22.4.220
32. Neuman, P., Strollo, M. K., Guterman, S., Rogers, W. H., Li, A., Rodday, A. M., et al. (2007). Medicare prescription drug benefit progress report: Findings from a 2006 national survey of seniors. Health Affairs (Millwood).
33. Oyugi, J. H., Byakika-Tusiime, J., Ragland, K., Laeyendecker, O., Mugerwa, R., Kityo, C., Mugyenyi, P., Quinn, T. C., & Bangsberg, D. R. (2007). Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. AIDS, 21, 1-7. doi: 10.1097/QAD.0b013e32802e6bfa
34. JJ Parienti V Massari D Descamps A Vabret E Bouvet B Larouze 2004 Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy Clinical Infectious Diseases 38 9 1311 1316 10.1086/383572
35. TS Rector PJ Venus 2004 Do drug benefits help Medicare beneficiaries afford prescribed drugs? Health Affairs (Millwood) 23 4 213 222 10.1377/hlthaff.23.4.213
36. S Reif K Whetten K Lowe J Ostermann 2006 Association of Unmet needs for support services with medication use and adherence among HIV-infected individuals in the Southeastern United States AIDS Care 18 4 277 283 10.1080/09540120500161868
37. MJ Robertson RA Clark ED Charlebois J Tulsky HL Long DR Bangsberg 2004 HIV seroprevalence among homeless and marginally housed adults in San Francisco American Journal of Public Health 94 7 1207 1217
38. Robinson, J. C. (2002). Renewed emphasis on consumer cost sharing in health insurance benefit design. Health Affairs (Millwood), Suppl Web Exclusives, W139-W154.
39. JC Robinson 2004 Reinvention of health insurance in the consumer era Journal of the American Medical Association 291 15 1880 1886 10.1001/jama.291.15.1880
40. L Ruiz R Paredes G Gomez J Romeu P Domingo N Perez-Alvarez 2007 Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients AIDS 21 2 169 178 10.1097/QAD.0b013e328011033a
41. BR Schackman KA Gebo RP Walensky E Losina T Muccio PE Sax 2006 The lifetime cost of current human immunodeficiency virus care in the United States Medical Care 44 11 990 997 10.1097/01.mlr.0000228021.89490.2a
42. YC Shih 1999 Effect of insurance on prescription drug use by ESRD beneficiaries Health Care Financing Review 20 3 39 54
43. SB Soumerai TJ McLaughlin D Ross-Degnan CS Casteris P Bollini 1994 Effects of a limit on Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia New England Journal of Medicine 331 10 650 655 10.1056/NEJM199409083311006
44. LA Spacek HM Shihab MR Kamya D Mwesigire A Ronald H Mayanja 2006 Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda Clinical Infectious Diseases 42 2 252 259 10.1086/499044
45. F Starace A Ammassari MP Trotta R Murri P De Longis C Izzo 2002 Depression is a risk factor for suboptimal adherence to highly active antiretroviral therapy Journal of Acquired Immune Deficiency Syndromes 31 Suppl 3 S136 S139
46. EA Storch JW Roberti DA Roth 2004 Factor structure, concurrent validity, and internal consistency of the beck depression inventory-Second edition in a sample of college students Depression and Anxiety 19 3 187 189 10.1002/da.20002
47. B Stuart C Zacker 1999 Who bears the burden of Medicaid drug copayment policies? Health Affairs (Millwood) 18 2 201 212 10.1377/hlthaff.18.2.201
48. R Tamblyn R Laprise JA Hanley M Abrahamowicz S Scott N Mayo 2001 Adverse events associated with prescription drug cost-sharing among poor and elderly persons Journal of the American Medical Association 285 4 421 429 10.1001/jama.285.4.421
49. CW Tseng RH Brook E Keeler WN Steers CM Mangione 2004 Cost-lowering strategies used by Medicare beneficiaries who exceed drug benefit caps and have a gap in drug coverage Journal of the American Medical Association 292 8 952 960 10.1001/jama.292.8.952
50. G van Servellen B Chang L Garcia E Lombardi 2002 Individual and system level factors associated with treatment nonadherence in human immunodeficiency virus-infected men and women AIDS Patient Care and STDS 16 6 269 281 10.1089/10872910260066705
51. Wilson, J., Axelsen, K., & Tang, S. (2005). Medicaid prescription drug access restrictions: exploring the effect on patient persistence with hypertension medications. American Journal of Managed Care, 11 Spec No, SP27-SP34.
52. AR Zolopa JA Hahn R Gorter J Miranda D Wlodarczyk J Peterson 1994 HIV and tuberculosis infection in San Francisco's homeless adults. prevalence and risk factors in a representative sample Journal of the American Medical Association 272 6 455 461 10.1001/jama.272.6.455